Abstract
The bioactive phospholipid lysophosphatidic acid (LPA) stimulates cell proliferation, migration and survival by acting on its cognate G-protein-coupled receptors. Aberrant LPA production, receptor expression and signalling probably contribute to cancer initiation, progression and metastasis. The recent identification of ecto-enzymes that mediate the production and degradation of LPA, as well as the development of receptor-selective analogues, indicate mechanisms by which LPA production or action could be modulated for cancer therapy.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Biomarkers, Tumor / analysis
-
Heterotrimeric GTP-Binding Proteins / metabolism
-
Humans
-
Lysophospholipids / analysis
-
Lysophospholipids / chemistry
-
Lysophospholipids / physiology*
-
Neoplasms / diagnosis
-
Neoplasms / etiology*
-
Receptors, Cell Surface / metabolism
-
Receptors, G-Protein-Coupled*
-
Receptors, Lysophosphatidic Acid
-
Signal Transduction
Substances
-
Biomarkers, Tumor
-
Lysophospholipids
-
Receptors, Cell Surface
-
Receptors, G-Protein-Coupled
-
Receptors, Lysophosphatidic Acid
-
Heterotrimeric GTP-Binding Proteins